A Phase II, randomised, observer-blind, controlled, multi-country study to rank different formulations of GSK Biologicals' investigational RSV vaccine (GSK3003891A), based on immunogenicity, reactogenicity and safety, when administered to healthy women, aged 18 - 45 years

Trial Profile

A Phase II, randomised, observer-blind, controlled, multi-country study to rank different formulations of GSK Biologicals' investigational RSV vaccine (GSK3003891A), based on immunogenicity, reactogenicity and safety, when administered to healthy women, aged 18 - 45 years

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs GSK 3003891A (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 30 Aug 2017.
    • 26 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 17 Nov 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top